UK-based AI drug discovery company e-therapeutics has secured GBP 28.90 million (~USD 37.9 million) in funding a round that saw participation from existing shareholders M&G Investment Management Limited and Richard Griffiths.
The company plans to allocate the raised funds to advance its multiple GalOmic pipeline assets toward clinical trials, further develop its HepNet computational platform, and to maintain a robust early pipeline. The company also plans to explore the option of listing on the Nasdaq in the foreseeable future.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.